This preliminary program is subject to change.

Scale-up of Pharmaceutical Isolation and Drying Operations


Description:
Isolation and drying operations are the center stage of the downstream processing for manufacturing a high quality API drug substance whether it is a small or a bio-molecule compound. Successful scale up of such operations is dependent on obtaining a good understanding of process thermodynamics, physical properties of the crystalline particles, and mechanical stress environment within the isolation equipment. Often unique approaches for isolation and drying are needed to ensure high product quality /yield and optimal cycle times. Product quality includes maintaining the desired physical properties and polymorphic form of the product. This session invites presentations on innovative approaches for isolation and drying covering topics as below: (1) Enhancements of filtration or drying operations through process improvements (small molecule) (2) Novel drying technologies for bulk API, including technologies for maintaining desired physical properties and isolation of small/nano-particles, and also new developments in continuous filtration and drying operations (3) Advances in physical property control and performance prediction. Examples include (a) technologies for avoiding particle attrition/agglomeration, polymorph transformation, amorphous formation/loss of crystallinity and (b) laboratory tools for predicting the occurrence or extent of such adverse affects. (4) New modeling approaches for filtration and drying. Examples include estimating cake resistance and compressibility, drying rate modeling, mechanism understanding, or identification of unique controlling parameters to achieve the desired target profile (5) Polymorphic transformation studies during drying leading to successful scale-up (6) Purification approaches of biomolecules (proteins, peptides and MAbs) through filtration/drying (7) Applications of PAT tools in the development of filtration and drying

Sponsor:
Pharmaceuticals


Chair:
Pavol Rajniak
Merck & Co., Inc.
Pharmaceutical Commercialization Technology
WP78-110, P.O. Box 4
West Point, PA 19486
Fax Number: 215-652-2821
Email: pavol_rajniak@merck.com

Co-Chair:
Joseph Kushner IV
Principal Scientist
Pfizer Worldwide Research and Development
Drug Product Design
Eastern Point Road
Groton, CT 06340
Phone Number: 860-686-1098
Email: joseph.kushner@pfizer.com


Papers:
Developing Improved Understanding of Spray Drying Through Process Modelling
Thoralf Hartwig, GlaxoSmithKline Ltd; Francois Ricard, GlaxoSmithKline Ltd; Ian C. Kemp, GlaxoSmithKline Ltd; Mark A. Pinto, Process Systems Enterprise; Sean K. Bermingham, Process Systems Enterprise
Development of a Laboratory and Mathematical Model to Predict Scale up Performance of an API Slurry Milling and Isolation Step
Edward Conder, Eli Lilly & Co; Kevin D. Seibert, Eli Lilly & Co.; Carla Luciani, Eli Lilly & Co; Eric Moher, Eli Lilly & Co.; Daniel Jarmer, Eli Lilly & Co.; Michael Phillips, Eli Lilly & Co
Manufacture and Control of a Hygroscopic Anhydrous API
Nathan Domagalski, Bristol-Myers Squibb Co.; Brendan C. Mack, Bristol-Myers Squibb Company; Amanda Rogers, Bristol-Myers Squibb Co.; Jose E. Tabora, Bristol Myers Squibb; Lindsay Hobson, Bristol-Myers Squibb Company
Elucidation of Drying Mechanisms of De-Solvation and the Establishment of a Drying Model
Daniel Hsieh, Bristol-Myers Squibb Company; Chenchi Wang, Bristol-Myers Squibb Company; Shih-Ying Chang, Bristol-Myers Squibb Company; San Kiang, Bristol-Myers Squibb Company
Multi-Scale Modeling of Pharmaceutical Spray Drying
Pavol Rajniak, Merck & Co., Inc.; Genong Li, Ansys Inc.; David Johnson, Merck & Co., Inc.; Rick Falk, Bend Research Inc; Justin D. Moser, Merck & Co., Inc.